[go: up one dir, main page]

MX2019001575A - Agentes terapeuticos para enfermedades neurodegenerativas. - Google Patents

Agentes terapeuticos para enfermedades neurodegenerativas.

Info

Publication number
MX2019001575A
MX2019001575A MX2019001575A MX2019001575A MX2019001575A MX 2019001575 A MX2019001575 A MX 2019001575A MX 2019001575 A MX2019001575 A MX 2019001575A MX 2019001575 A MX2019001575 A MX 2019001575A MX 2019001575 A MX2019001575 A MX 2019001575A
Authority
MX
Mexico
Prior art keywords
neurodegenerative diseases
therapeutic agents
leucine
treatment
present disclosure
Prior art date
Application number
MX2019001575A
Other languages
English (en)
Other versions
MX383499B (es
Inventor
Strupp Michael
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59859424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019001575(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1613829.9A external-priority patent/GB201613829D0/en
Priority claimed from GBGB1702551.1A external-priority patent/GB201702551D0/en
Priority claimed from GBGB1705766.2A external-priority patent/GB201705766D0/en
Priority claimed from GBGB1706867.7A external-priority patent/GB201706867D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MX2019001575A publication Critical patent/MX2019001575A/es
Publication of MX383499B publication Critical patent/MX383499B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona el tratamiento de enfermedades neurodegenerativas el cual comprende administrar acetil-leucina o una sal farmacéuticamente aceptable del mismo.
MX2019001575A 2016-08-11 2017-08-11 Agentes terapeuticos para enfermedades neurodegenerativas MX383499B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1613829.9A GB201613829D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1702551.1A GB201702551D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1705766.2A GB201705766D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1706867.7A GB201706867D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
PCT/IB2017/054929 WO2018029658A1 (en) 2016-08-11 2017-08-11 Therapeutic agents for neurodegenerative diseases

Publications (2)

Publication Number Publication Date
MX2019001575A true MX2019001575A (es) 2019-08-01
MX383499B MX383499B (es) 2025-03-14

Family

ID=59859424

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019001575A MX383499B (es) 2016-08-11 2017-08-11 Agentes terapeuticos para enfermedades neurodegenerativas
MX2021006901A MX2021006901A (es) 2016-08-11 2019-02-07 Agentes terapeuticos para enfermedades neurodegenerativas.
MX2024004439A MX2024004439A (es) 2016-08-11 2024-04-11 Agentes terapeuticos para enfermedades neurodegenerativas

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2021006901A MX2021006901A (es) 2016-08-11 2019-02-07 Agentes terapeuticos para enfermedades neurodegenerativas.
MX2024004439A MX2024004439A (es) 2016-08-11 2024-04-11 Agentes terapeuticos para enfermedades neurodegenerativas

Country Status (28)

Country Link
US (3) US12144792B2 (es)
EP (3) EP3583940A1 (es)
JP (3) JP6957602B2 (es)
KR (4) KR20220093385A (es)
CN (4) CN109789114A (es)
AU (3) AU2017308865B2 (es)
BR (1) BR112019002730A2 (es)
CA (1) CA3033564A1 (es)
CY (1) CY1121930T1 (es)
DK (1) DK3416631T3 (es)
ES (1) ES2733677T3 (es)
HR (1) HRP20191055T1 (es)
HU (1) HUE045043T2 (es)
IL (3) IL310801A (es)
LT (1) LT3416631T (es)
MA (2) MA43828B1 (es)
MD (1) MD3416631T2 (es)
ME (1) ME03454B (es)
MX (3) MX383499B (es)
PL (1) PL3416631T3 (es)
PT (1) PT3416631T (es)
RS (1) RS59048B1 (es)
RU (1) RU2756519C2 (es)
SG (1) SG11201901063SA (es)
SI (1) SI3416631T1 (es)
SM (1) SMT201900370T1 (es)
TN (1) TN2019000033A1 (es)
WO (1) WO2018029658A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10219815B2 (en) 2005-09-22 2019-03-05 The Regents Of The University Of Michigan Histotripsy for thrombolysis
US11135454B2 (en) 2015-06-24 2021-10-05 The Regents Of The University Of Michigan Histotripsy therapy systems and methods for the treatment of brain tissue
CA3033564A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Acetyl-leucine for neurodegenerative diseases
MA43876B1 (fr) 2016-08-11 2019-04-30 Intrabio Ltd Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
US11793782B2 (en) * 2017-10-18 2023-10-24 Intrabio Limited Therapeutic agents for neurodegenerative diseases
LT3752141T (lt) 2018-02-15 2024-07-10 Intrabio Ltd Acetil-leucinas, skirtas panaudoti gydant neramių kojų sindromą
WO2020113083A1 (en) 2018-11-28 2020-06-04 Histosonics, Inc. Histotripsy systems and methods
WO2020115715A1 (en) * 2018-12-06 2020-06-11 Intrabio Ltd. Deuterated analogs of acetyl-leucine
HRP20241150T1 (hr) * 2019-03-02 2024-11-22 Intrabio Ltd (n-)acetil-l-leucin za uporabu u liječenju traumatske ozljede mozga
US20220346699A1 (en) * 2019-09-17 2022-11-03 Hoffmann-La Roche Inc. Improvements in Personalized Healthcare for Patients with Movement Disorders
US20230051742A1 (en) * 2020-01-13 2023-02-16 Intrabio Ltd. Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
JP2023526517A (ja) * 2020-05-22 2023-06-21 イントラビオ エルティーディー 運動失調症を治療するためのアセチルロイシンと４－アミノピリジン又はアセタゾラミドとの組合せ
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease
AU2023366591A1 (en) 2022-10-28 2025-04-24 Histosonics, Inc. Histotripsy systems and methods
US12446905B2 (en) 2023-04-20 2025-10-21 Histosonics, Inc. Histotripsy systems and associated methods including user interfaces and workflows for treatment planning and therapy
WO2025151578A1 (en) * 2024-01-12 2025-07-17 Intrabio Inc. N-acetyl-leucine for use in the treatment of prodromal alpha-synucleinopathies
WO2025163129A1 (en) * 2024-02-01 2025-08-07 Intrabio Ltd. Acetyl-leucine for treating parkinson´s disease
US12403111B2 (en) 2024-02-02 2025-09-02 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders
WO2025175092A1 (en) * 2024-02-14 2025-08-21 Intrabio Inc. Acetyl leucine for treating syngap1-related disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
FR2905600B1 (fr) 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
WO2008101692A2 (en) 2007-02-22 2008-08-28 Beiersdorf Ag Cosmetic and pharmaceutical applications of n-acetylhydroxyproline
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
CN105764522A (zh) * 2013-10-28 2016-07-13 诺雷克斯股份有限公司 Nmda受体调节剂及其前药、盐和用途
BR112018071547A2 (pt) 2016-04-19 2019-03-06 Intrabio Ltd acetil-leucina ou um sal farmaceuticamente aceitável desta
CA3033564A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Acetyl-leucine for neurodegenerative diseases

Also Published As

Publication number Publication date
EP3416631A1 (en) 2018-12-26
CN116492328A (zh) 2023-07-28
IL264641A (en) 2019-04-30
IL310799A (en) 2024-04-01
AU2017308865B2 (en) 2023-04-13
BR112019002730A2 (pt) 2019-05-14
JP6957602B2 (ja) 2021-11-02
CN109789114A (zh) 2019-05-21
CA3033564A1 (en) 2018-02-15
RU2021128045A (ru) 2021-11-16
IL264641B2 (en) 2024-07-01
JP2022003085A (ja) 2022-01-11
JP2019524822A (ja) 2019-09-05
PL3416631T3 (pl) 2019-11-29
RU2756519C2 (ru) 2021-10-01
IL264641B1 (en) 2024-03-01
KR102785448B1 (ko) 2025-03-21
MX2024004439A (es) 2025-11-03
MX383499B (es) 2025-03-14
KR20220093385A (ko) 2022-07-05
TN2019000033A1 (fr) 2020-07-15
AU2023202121A1 (en) 2023-05-04
AU2017308865A1 (en) 2019-02-21
RU2019106506A (ru) 2020-09-17
CN116459244A (zh) 2023-07-21
AU2023202121B2 (en) 2025-01-23
HRP20191055T1 (hr) 2019-09-06
US12144792B2 (en) 2024-11-19
KR20250042197A (ko) 2025-03-26
MA43828B1 (fr) 2019-09-30
MA43828A (fr) 2018-12-26
MD3416631T2 (ro) 2019-09-30
SG11201901063SA (en) 2019-03-28
EP4467195A2 (en) 2024-11-27
RU2019106506A3 (es) 2020-10-29
EP3583940A1 (en) 2019-12-25
KR20240068761A (ko) 2024-05-17
JP2023175762A (ja) 2023-12-12
US20200179320A1 (en) 2020-06-11
US20230210799A1 (en) 2023-07-06
ME03454B (me) 2020-01-20
PT3416631T (pt) 2019-07-11
AU2025202077A1 (en) 2025-04-10
CY1121930T1 (el) 2020-10-14
DK3416631T3 (da) 2019-07-15
US20240189267A1 (en) 2024-06-13
EP4467195A3 (en) 2025-03-19
EP3416631B1 (en) 2019-05-15
MA47521A (fr) 2021-04-21
LT3416631T (lt) 2019-08-26
RS59048B1 (sr) 2019-08-30
CN121081445A (zh) 2025-12-09
HUE045043T2 (hu) 2019-12-30
SI3416631T1 (sl) 2019-09-30
SMT201900370T1 (it) 2019-09-09
KR20190039227A (ko) 2019-04-10
IL310801A (en) 2024-04-01
WO2018029658A1 (en) 2018-02-15
KR102413756B1 (ko) 2022-06-27
ES2733677T3 (es) 2019-12-02
MX2021006901A (es) 2021-07-07

Similar Documents

Publication Publication Date Title
MX2019001575A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
DOP2019000187A (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
MX2017003819A (es) Macrociclos peptidomimeticos y formulaciones de los mismos.
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
AR101740A1 (es) Terapia de combinación y composiciones
CL2019000844A1 (es) Compuesto de piridina.
MX2015015228A (es) Sobetirome en el tratamiento de enfermedades de mielinizacion.
EA201692436A1 (ru) Медицинское применение
CR20140086A (es) Tratamientos de combinación para hepatitis c
CL2017000050A1 (es) Terapia de combinación para el cáncer
MX2017004558A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
SV2016005313A (es) Derivados de carboxamida
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MX2019001577A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
MX394782B (es) Compuestos para el tratamiento de enfermedades asociadas con una disfunción mitocondrial.
DOP2014000030A (es) Procedimientos para la fabricación de medicamentos útiles para el tratamiento de infecciones virales
MX2018014915A (es) Tratamiento de enfermedades colestasicas intrahepaticas.
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
GT201700227A (es) Derivados de aminohidrotiazina fusionados con tetrahidrofurano los cuales son utiles en el tratamiento de la enfermedad de alzheimer
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas
CL2018002930A1 (es) (+)-azasetron para uso en el tratamiento de desórdenes de oído.
AR115865A2 (es) Compuestos terapéuticos
CL2015001705A1 (es) Uso de pidotimod para tratar la psoriasis